Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term growth story centers on immuno-oncology and vaccines

Merck & Co. stock remains anchored by its leadership in oncology and vaccines, with flagship cancer drug Keytruda and a broad late-stage pipeline underpinning the long-term narrative for one of the largest healthcare names in the S&P 500.

Merck & Co., Inc. (ISIN US58933Y1055) is one of the largest U.S.-listed pharmaceutical companies and a key healthcare constituent of the S&P 500. The company’s investment case continues to be driven by oncology, vaccines, and cardiometabolic therapies, supported by a broad late-stage pipeline and significant global scale across research, manufacturing, and commercialization.

Oncology and immunotherapy remain central

Oncology is the strategic centerpiece of Merck & Co., Inc., with its immuno-oncology franchise positioned as a leading therapy option for several major cancer types. The company’s flagship programmed cell death protein 1 (PD-1) inhibitor is approved across a wide range of indications, from metastatic melanoma and non-small cell lung cancer to renal cell carcinoma and certain head and neck cancers, providing a diversified revenue base within oncology.

In many key markets, this therapy is used either as a monotherapy or in combination with chemotherapy or targeted agents, reflecting a strategy that aims to extend survival across earlier lines of treatment and different tumor types. A substantial portion of Merck’s current oncology research focuses on expanding these indications further, including adjuvant and neoadjuvant settings where treatment is given before or after surgery to reduce the risk of recurrence.

Merck is also pursuing a wide range of combination regimens that pair its immunotherapy backbone with other mechanisms of action, such as antibody-drug conjugates, novel checkpoint inhibitors, and agents targeting tumor microenvironment pathways. This multi-pronged approach seeks to unlock incremental benefit beyond monotherapy and to address tumors that are less responsive to existing treatments.

Beyond the flagship PD-1 inhibitor, Merck has assembled an oncology portfolio that includes precision medicines, cell-cycle regulators, and targeted therapies obtained both through internal development and external business development. These assets are designed to complement the core immunotherapy platform and to address specific genetic or molecular markers in cancer cells, allowing for more personalized treatment strategies where biomarkers guide therapy selection.

Regulatory interactions across major regions, including the U.S., Europe, and key Asian markets, remain critical as Merck progresses its oncology programs through late-stage trials. Approvals in additional tumor types or earlier disease settings can meaningfully extend the revenue life cycle of established products, partially offsetting long-term patent-expiry risk that is inherent in the pharmaceutical industry.

Vaccines, cardiometabolic and animal health

Outside oncology, Merck & Co., Inc. operates a sizeable vaccines business that targets both pediatric and adult populations, providing protection against diseases such as human papillomavirus, pneumococcal infections, hepatitis, and others. Vaccines typically feature high barriers to entry, supported by complex manufacturing processes, multi-year development timelines, and extensive safety databases.

The company’s vaccine portfolio benefits from long-running immunization programs and public-health recommendations, and demand often correlates with birth cohorts, aging populations, and the strength of healthcare infrastructure across geographies. For investors, vaccines can offer a different revenue profile than traditional small-molecule drugs, with long product lifecycles and a strong emphasis on manufacturing reliability and supply continuity.

Merck is also active in cardiometabolic diseases, where it has marketed therapies targeting conditions such as type 2 diabetes and cardiovascular risk factors. While competition in these segments is intense and includes a range of branded and generic products, cardiometabolic diseases remain a large and growing area of unmet need worldwide, with rising prevalence tied to demographic and lifestyle trends.

The company’s animal health division contributes a complementary revenue stream through pharmaceuticals, vaccines, and health-management solutions for both companion animals and livestock. This business benefits from trends such as the increasing medicalization of pets and continued focus on productivity and disease prevention in food-producing animals, providing additional diversification versus the core human-health portfolio.

Keytruda as a flagship therapy

A central commercial and clinical pillar for Merck & Co., Inc. is Keytruda, its PD-1 blocking antibody used in the treatment of various cancers. Keytruda has become one of the world’s highest-selling cancer medicines, reflecting broad label coverage across multiple tumor types and use in both first-line and subsequent lines of therapy.

The success of Keytruda rests on evidence showing improved survival in a range of clinical settings. Over the years, the drug has received approvals for indications including, but not limited to, non-small cell lung cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, and certain types of colorectal and gastric cancers, among others. These approvals often followed large randomized clinical trials comparing Keytruda-based regimens with then-standard therapies.

Keytruda is administered intravenously and typically given on a regular schedule, such as every three or six weeks, depending on the regimen and indication. Its mechanism involves reactivating T-cells in the immune system that have been inhibited by tumor-expressed PD-L1 or related pathways, thereby enabling the immune system to recognize and attack cancer cells more effectively. This mode of action has reshaped treatment algorithms in several malignancies.

To maintain its leadership position, Merck has invested in ongoing Keytruda trials aimed at moving treatment to earlier stages of disease, including adjuvant and neoadjuvant settings where the goal is to prevent recurrence after surgery or to shrink tumors before surgery. Success in these settings can extend the duration of therapy per patient and broaden the eligible patient pool, reinforcing the drug’s status as a cornerstone of modern oncology.

Merck is also exploring new formulations and dosing strategies for Keytruda, including subcutaneous delivery options that could offer greater convenience for patients and healthcare providers if successfully developed and approved. Such innovations can help defend market share against competing immunotherapies and next-generation agents that target similar checkpoints or related immune pathways.

Merck & Co. stock and market role

Merck & Co., Inc. stock trades on the New York Stock Exchange under the ticker MRK, denominated in U.S. dollars. As a large-cap constituent of the S&P 500 healthcare sector, the company tends to be widely held by institutional investors and is often used as a core exposure to global pharmaceuticals and immuno-oncology within diversified equity portfolios.

Merck & Co., Inc. at a glance

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: MRK
• Exchange: New York Stock Exchange (NYSE)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500